Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells + repetitive electromagnetic stimulation
- Development stage
- Unknown
- Lead developer
- Bioretina Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
Wharton's jelly-derived mesenchymal stem cells (WJ-MSC) combined with repetitive electromagnetic stimulation (rEMS) is an experimental regenerative therapy developed by Ankara University Technopolis (Ankara Universitesi Teknokent) and Bioretina Biotechnology for the treatment of toxic optic neuropathy. The therapy utilizes the paracrine and immunomodulatory properties of WJ-MSCs, which secrete neurotrophic factors and anti-inflammatory molecules to protect damaged optic nerve axons and promote mitochondrial ATP synthesis. This is complemented by rEMS, delivered via the Magnovision™ helmet device, which uses low-frequency electromagnetic fields to stimulate the visual pathways, rearrange ion channel balances, and restore axoplasmic flow. The combination has been evaluated in Phase 3 clinical trials for patients with vision loss resulting from exposure to toxins such as methanol, sildenafil, and amiodarone.
- Brand names
- Magnovision
- Other names
- Wharton jelly derived mesenchymal stem cell-Ankara Universitesi Teknokent-toxic optic neuropathyWJ-MSC and rEMS combinationBioretina Inc Ankara University Technopolis
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells + repetitive electromagnetic stimulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells + repetitive electromagnetic stimulation.